[HTML][HTML] Enteric coating of tablets containing an amorphous solid dispersion of an enteric polymer and a weakly basic drug: a strategy to enhance in vitro release
Recent work has highlighted that amorphous solid dispersions (ASDs) containing
delamanid (DLM) and an enteric polymer, hypromellose phthalate (HPMCP), appear to be …
delamanid (DLM) and an enteric polymer, hypromellose phthalate (HPMCP), appear to be …
[HTML][HTML] Trends in amorphous solid dispersion drug products approved by the US Food and Drug Administration between 2012 and 2023
Abstract Forty-eight (48) drug products (DPs) containing amorphous solid dispersions
(ASDs) have been approved by the US Food and Drug Administration in the 12-year period …
(ASDs) have been approved by the US Food and Drug Administration in the 12-year period …
A Commentary on Co-Processed API as a Promising Approach to Improve Sustainability for the Pharmaceutical Industry
Pharmaceutical products represent a meaningful target for sustainability improvement and
emissions reduction. It is proposed here that rethinking the standard, and often linear …
emissions reduction. It is proposed here that rethinking the standard, and often linear …